Joel F. Habener

Harvard University, HHMI, Cambridge, MA, United States 
"Joel Habener"
Mean distance: 16.42 (cluster 11)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Habener JF, Stanojevic V. (2017) Pancreas and Not Gut Mediates the GLP-1-Induced Glucoincretin Effect. Cell Metabolism. 25: 757-758
Stanojevic V, Habener JF. (2015) Evolving function and potential of pancreatic alpha cells. Best Practice & Research. Clinical Endocrinology & Metabolism. 29: 859-71
Elahi D, Ruff DA, Carlson OD, et al. (2015) Does GLP-1 suppress its own basal secretion? Endocrine Research. 1-5
Tomas E, Stanojevic V, McManus K, et al. (2015) GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice. Diabetes. 64: 2409-19
Elahi D, Angeli FS, Vakilipour A, et al. (2014) GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs. Peptides. 59: 20-4
Kemp DM, Habener JF. (2014) Glucagon and Glucagon-Like Peptides Reference Module in Biomedical Research
Unger RH, Berglund ED, Habener JF, et al. (2013) Dissecting the actions of widely used diabetes drugs. Nature Medicine. 19: 272-3
Habener JF, Stanojevic V. (2013) Alpha cells come of age. Trends in Endocrinology and Metabolism: Tem. 24: 153-63
Habener JF, Stanojevic V. (2012) α-cell role in β-cell generation and regeneration. Islets. 4: 188-98
Liu Z, Stanojevic V, Brindamour LJ, et al. (2012) GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity. The Journal of Endocrinology. 213: 143-54
See more...